in situ localization of AGE-modified proteins in peripheral nerve obtained by biopsy or at autopsy from diabetic patients by using a monoclonal antibody for Ne-carboxymethyllysine (CML), an AGE [1, 22] . We also performed histological examinations on these nerve samples and explored whether there is a relationship between AGE accumulation and clinicopathological changes. For comparison, peripheral nerves of non-diabetic subjects were examined.
Subjects and methods
Subjects. Ten peripheral nerve samples were obtained from 5 non-insulin-dependent diabetic patients and 5 non-diabetic control subjects. Clinical characteristics of the subjects in this study are summarized in Table 1 . Nerve specimens were obtained by biopsy in 4 cases and at autopsy in the remaining 6 cases. Diagnosis and classification of diabetes were based on the criteria of the National Diabetes Data Group [23] . In the biopsy cases, 2 diabetic patients (cases 1 and 3) showed marked hyperglycaemia with elevated HbA 1 c values (17.6 and 9.8 % at the time of admission) and suffered from severe pain in lower extremities. The pain continued for more than 6 months after the correction of hyperglycaemia with insulin treatment in both cases. Nerve biopsy was performed to examine whether diabetes-unrelated disorders such as vasculitis were underlying the chronic painful neuropathy. Case 2 presented with skin ulcers in the right toe and sole. Sural nerve sample was obtained when amputation was carried out on this patient. The other 2 diabetic patients (cases 4 and 5) had long-standing diabetes but died of non-diabetic causes lacking apparent neuropathic symptoms. The left sural nerves were taken at autopsy in these patients. The subjects used as non-diabetic controls had no history of diabetes and had fasting plasma glucose levels less than 6.1 mmol/l. In case 6 the right peroneal nerve was taken at the time of the leg operation and the saphenous nerve in the left leg was taken at the time of autopsy in case 10. In the biopsy cases, information including the nature, purpose, and potential risks of the operation was given before surgery to all the patients, who thereafter consented to the biopsy. Ethical committee approval was obtained from the Hirosaki University School of Medicine.
Tissue sampling and histological examinations. Peripheral nerve specimens 1±2 cm in length were obtained by total fascicular biopsy and at autopsy. The nerve specimens were fixed with 4 % paraformaldehyde in 0.1 mol/l phosphate buffer (pH 7.4) overnight and then cut into pieces of 3 mm in length. For morphological evaluation, a portion of the nerve sample in each case was postfixed with 1 % osmium tetroxide. After dehydration with graded series of ethanol, they were embedded in Epon 812 and polymerized. Semithin cross-sections of the nerve fascicle (1.0 mm in thickness) were obtained with an LKB Ultramicrotome (Bromma, Sweden) and subjected to light microscopic observations after staining with 1 % pphenylenediamine.
Morphometric analyses of myelinated nerve fibers were performed on 1 % p-phenylenediamine-stained semithin cross-sections (1.0 mm) using a VIDAS image analysis system (Carl Zeiss, Tokyo) [24] . Myelinated fiber density was obtained by measurements of total myelinated fiber number divided by total fascicular area. When two or more nerve fascicles were observed, only the largest fascicle was used for the measurement. For the measurement of myelinated fiber diameter, we delineated the outer myelin border to obtain the fiber area, which was then converted to fiber diameter by assuming the area as a circle. More than 200 myelinated fibers were measured for this purpose in each case.
Immunohistochemistry. Immunohistochemical staining was performed by streptavidin biotin complex method [25, 26] . Briefly, after fixation with 4 % paraformaldehyde, nerve samples of 3 mm long were frozen in dry ice-cooled isopentane after cryoprotection by incubation with 1.5 and 2.3 mol/l sucrose in 0.1 mol/l phosphate buffer (pH 7.4) for 8 and 12 h at 4°C, respectively. The frozen sections were obtained by a cryostat (Frigocut 2800 E, Reichert-Jung, Cambridge Instruments, Nuûloch, Germany). At least 10 transverse sections, 40 mm thick in each case, were obtained. The sections were preincubated in a 0.3 % H 2 O 2 solution in phosphate buffered saline (PBS) for 20 min at room temperature to inhibit background staining due to endogenous peroxidase activity. After washing with PBS for 10 min at least 6 times at 4°C, the sections were Non-diabetic control patients had blood glucose levels less than 6.1 mmol/l. ND, not determined incubated with 10 % normal rabbit serum (Histofine, Nichirei, Tokyo) for 2 h at room temperature to inhibit non-specific binding. The sections were then exposed to primary antibody (mouse monoclonal antibody for AGE) [1, 22] diluted to 1.0 mg/ml with PBS containing 1 % bovine serum albumin (BSA) and 0.1 % sodium azide for 48 h at 4°C. After washing with PBS three times for 10 min, secondary antibody (rabbit biotinylated anti-mouse IgA + IgG + IgM antibody: Histofine) was added for 2 h at room temperature. The sections were then incubated with peroxidase-conjugated streptavidin for 2 h at room temperature. To visualize the immunoreactions, sections were incubated with diaminobenzidine (DAB) in PBS containing 0.025 % cobalt chloride, 0.02 % nickel ammonium sulfate, and 0.065 % sodium azide. The procedure for the observation by a confocal laser scan microscope was the same as that described for application of the secondary antibody. It was followed by a rinse in PBS and incubation with fluorescein isothiocyanate (FITC)-labelled goat anti-rabbit IgG antibody for 16 h at 4°C. The stained sections were observed by a laser scan microscope (LSM310; Carl Zeiss). The scanning conditions including contrast, brightness level and pinhole size were set constant throughout the whole observation period for both control and diabetic samples.
Immunoelectron microscopy. The sections stained with anti-AGE-BSA antibody were osmicated (1 % osmium tetroxide) in 0.1 mol/l phosphate buffer (pH7.4) and embedded in Epon 812. Ultrathin sections were obtained with a ultramicrotome and examined with a JEOL 2000 electron microscope (NihonDenshi, Tokyo, Japan) after staining with lead citrate for 5 min or without staining.
Negative control and specificity of primary antibody. Immunostainings for negative control were performed by replacing the primary antibody by normal mouse serum. For specificity of primary antibody, preincubation of the primary antibody with an excess amount of AGE-BSA for 1 h at room temperature was also carried out. Following these preparations, the sections were processed to immunostaining as described above and analysed together with the other sections without these pretreatment procedures.
Statistical analysis. All morphometric analyses and evaluation for intensity of immunoreactivity for AGE in each case were performed in a blinded manner. The significance of differences between the mean values of diabetic and non-diabetic control patients was analysed by Mann-Whitney U-test (StatView-J 4.11). Relationships between variables were assessed by calculating Pearsons' simple correlation coefficients. A p-value less than 0.05 was considered statistically significant.
Results
Histological examinations. By light microscopy diabetic patients showed apparent myelinated fiber loss in Cases 1, 2, 3 and 4 in which myelinated fiber density was reduced when comparing with that in non-diabetic nerves ( Table 2 ). The remaining myelinated fibers underwent active fiber degeneration and myelin breakdown. Mean fiber diameter was not altered in diabetic nerves compared with non-diabetic nerves. Endoneurial microvessels of diabetic patients showed narrowed lumens and thickened walls. No vasculitic changes were detected. By contrast, there were no apparent fiber loss in non-diabetic nerve samples and only a few degenerative fibers were noted. Walls of endoneurial microvessels appeared to be thinner compared with those in diabetic nerves.
Immunohistochemistry. Immunohistochemical examination with light microscopy demonstrated that AGE was located in the perineurium, axons and Schwann cells of myelinated fibers, endothelial cells and pericytes of endoneurial microvessels both in diabetic and non-diabetic control nerves (Fig. 1) . In addition, there were scattered positive reactions in areas of unmyelinated fibers in diabetic nerves. Such endoneurial reactions particularly of microvessels and perineurium were strong in diabetic nerves but obscure in non-diabetic nerves (Fig. 1) . Occasionally, interstitial fibroblasts showed positive reactions. When the primary antibody was replaced by normal mouse serum or preincubated with AGE-BSA, both preparations showed diminished immunostaining. However, labellings were occasionally observed in the axons and Schwann cells of myelinated fibers, which may be Results from immunofluorescence analysis with a confocal laser scan microscopy were comparable to those of immunoperoxidase staining (Fig. 2) . AGE was distributed in the cytoplasm of Schwann cells, endothelial cells and pericytes. In addition, isolated oval or polygonal cells presumed to be macrophages were positive both in control and diabetic nerves. In contrast to immunoperoxidase staining, positive reactions were totally abolished when the primary antibody was replaced by normal mouse serum and when the sections were preincubated with AGE-BSA.
When the intensity of immunostaining signals was graded as ±, none; ± , equivocal; + , weak; + + , moderate; + + + , strong, most of perineurial and endoneurial tissue components in diabetic nerves were scored as high grade (Table 3) . Perineurial cells and myelinated axons in non-diabetic nerves also showed strong reactions, whereas differences in the staining intensities between diabetic and non-diabetic nerves were most conspicuous in endothelial cells and pericytes of endoneurial microvessels. When the graded intensity was numerically scored as ±, 0; ± , 0.5; + , 1; + + , 2; and + + + , 3; the overall intensity as a total sum of each of the scores of tissue components was significantly increased in diabetic nerves as compared with non-diabetic control nerves (p < 0.01) (Fig. 3) .
The overall intensity was not correlated with age or duration of diabetes, but there was a significant negative correlation between the overall intensity and myelinated fiber density (Fig. 4) .
Immunoelectron microscopy. At the electron microscopic levels, positive reactions were depicted as irregular deposition of black peroxidase reactions. There were focally aggregated deposits both intraand extracellularly. They located in the perineurial collagens, cytoplasm of perineurial cells and their basement membranes (Fig. 5A) as well as the cytoplasm of endothelial cells and pericytes of endoneurial microvessels (Fig. 5B) . The axoplasm and cytoplasm of Schwann cells of both unmyelinated and myelinated fibers showed focally strong positive reactions (Fig. 5C, D) . Fibroblasts and macrophages 
Discussion
In the present study, we demonstrated the localization of immunoreactive AGE in the peripheral nerve of diabetic and non-diabetic patients. The reaction products were demonstrated both intra-and extracellularly in perineurial and endoneurial tissues as well as microvessels. The overall staining intensity was significantly increased in diabetic nerves compared with non-diabetic nerves, although strong reactions were also found in perineurial cells and axons of myelinated fibers in non-diabetic nerves. We could not detect an apparent age-related increase in AGE deposition. Peripheral nerve is thus likely to undergo excessive glycation in the diabetic condition as occurs in other diabetic tissues [27] . The current data has also shown that the overall intensity of AGE reactions correlated with myelinated fiber loss, implicating the role of the glycation process in the cause and development of diabetic neuropathy.
The primary monoclonal antibody used in this study was generated by using AGE-modified BSA as an immunogen in mice [22] . The major epitope of this antibody was recently found to be an Ne-(carboxymethyl)lysine(CML)-modified adduct [28] . Various AGE-modified proteins including peptides and lysine derivatives all reacted with this antibody [22] . These findings suggested that whatever the protein 
±, negative; ±, equivocal; +, positive; ++, moderately positive; +++, strongly positive Relationships between the intensity scores of AGE reactions and age (a), duration of diabetes (b) and myelinated fiber density (c). Scores of diabetic nerves R; non-diabetic control nerves . No significant correlation is detected between the intensity and age or duration of diabetes, whereas the inverse correlation with myelinated fiber density is significant (p < 0.001)
is, common AGE products containing an epitope of CML are produced after progressive addition of glucose. Besides the modification of the Amadori products into CML with advancement of the glycation process, CML adducts of AGE are also formed by oxidative cleavage of the Amadori products at a relatively early stage of non-enzymatic glycation [29] . Intracellular as well as extracellular deposition of AGE detected in this study may therefore be the results of hyperglycaemia-induced in situ accumulation of glycation products or secondary products caused by oxidative stress. It remains unclear, however, whether other non-CML-type AGE may co-localize intracellularly or extracellularly with CML-type AGE or whether topographic distribution of CML is different from non-CML-type AGE.
In the present study, CML-type AGE was found in the cytoplasm of myelinated and unmyelinated fibers and endoneurial microvessels. Although overall reactions were intensified in diabetic nerve, the localization of AGE in nerve fibers did not appear to be directly associated with the pathologic processes of nerve fiber degeneration. These results do not necessarily undermine the significance of enhanced glycation in the pathogenesis of diabetic neuropathy when taking into consideration the biological action of AGE such as free radical formation, NO depletion and abnormal biological signalling [10, 30±32] . It is of note that perineurial cells and their basement membranes as well as perineurial collagens reacted with AGE. Perineurial cells and their basement membranes are thought to play a crucial role in the maintenance of perifascicular diffusion barrier to the macromolecules such as AGE-modified proteins [33, 34] . It may be possible that the excessive accumulation of AGE-modified adducts in the perineurium as well as endoneurial microvasculature alters the endoneurial microenvironment and microcirculation and thereby contributes to the development of peripheral neuropathy in diabetes.
Our ultrastructural examinations revealed that intracellular AGE did not have specific affinity with cytoplasmic organelles but rather distribute non-randomly as electron dense aggregates. It has been shown that fractions of tubulin as well as neurofilament are glycated in the peripheral nerve of streptozotocin diabetic rats [35±37] . Preservation of axoplasmic tubulin and neurofilaments is sometimes difficult in immunoelectron microscopic preparations. Such methodological problems may have caused difficulty when identifying the susceptible organelles, but the diffuse aggregation of reaction products on the subcellular structures of microtubules as well as neurofilaments is in keeping with the previous findings of excessive glycation of tubulin and neurofilaments in nerve of diabetic animal models [35±37] . The glycation of such axonal components may result in the impairment of axonal flow and impaired impulse propagation and thereby functional and structural abnormalities.
In summary, we clearly demonstrated the in situ localization of AGE in the peripheral nerve, which was augmented in diabetic patients and associated with myelinated fiber loss. We could not find, however, a direct link between AGE deposition and pathological changes of nerve fibers. The number of the nerves examined in this study was too small to lead to any conclusion on the specific role of glycation in the pathogenesis of diabetic neuropathy. Further studies are warranted to elucidate the mechanisms by which the processes of AGE formation are involved in the pathogenesis of diabetic neuropathy.
